There is no vaccine for Lyme disease currently available. The only one ever marketed in the United States, called LYMErix, was pulled from the market in 2002. However, a new vaccine candidate is in late-stage clinical trials and could reach the market within the next few years.
What Happened to the First Lyme Vaccine
LYMErix, made by SmithKline Beecham, hit the market in 1998 and was withdrawn just four years later. The manufacturer cited poor sales, but those poor sales were driven by something deeper: a class-action lawsuit filed by more than 400 patients who claimed they developed Lyme-like symptoms after getting the vaccine. The safety concerns, even without definitive proof of harm, eroded public confidence enough to make the product commercially unviable.
The result was a two-decade gap with no human Lyme vaccine on the market, even as Lyme disease cases continued to climb across the northeastern and upper midwestern United States.
The Vaccine Candidate Closest to Approval
Pfizer and the biotech company Valneva are developing a vaccine called VLA15, which targets the outer surface protein of the bacteria that cause Lyme disease. It’s currently in a Phase 3 clinical trial called VALOR, which enrolled over 12,500 participants. That’s the final stage of testing before a company can apply for regulatory approval.
Efficacy results from the trial have not yet been published. Pfizer originally planned to submit VLA15 for full FDA approval in 2025, but issues with the clinical trials pushed that timeline back. The current estimate is a submission to the FDA in 2026, meaning the earliest you could realistically expect to receive this vaccine, if approved, would be 2026 or 2027.
An Experimental Approach Using mRNA
Separately from VLA15, researchers are exploring an entirely different strategy: instead of targeting the Lyme bacteria directly, this approach uses mRNA technology to train your immune system to recognize proteins in tick saliva. The goal is to trigger an immune reaction at the bite site (redness, swelling, itching) that you’d notice quickly, prompting you to remove the tick before it feeds long enough to transmit the bacteria. Lyme transmission typically requires a tick to be attached for at least 36 hours, so early detection matters enormously.
In lab studies, mRNA-based vaccines produced a more noticeable and earlier skin reaction at the bite site compared to other delivery methods. This work is still in early research stages and years away from human trials, but it represents a fundamentally different way of thinking about tick-borne disease prevention: stopping the tick rather than fighting the bacteria.
Why Dogs Have a Lyme Vaccine and You Don’t
If you have a dog, your vet may have already offered a Lyme vaccine. Several are commercially available for dogs. The reason for this gap comes down to the regulatory bar: veterinary vaccines face less rigorous safety testing requirements than human vaccines, and the threshold for acceptable side effects is different. The LYMErix controversy made pharmaceutical companies especially cautious about bringing a new human Lyme vaccine to market.
Interestingly, the canine vaccines also have limitations. In one study tracking 183 vaccinations over 13 months, dogs on a standard two-dose schedule showed declining antibody levels between four and twelve months, likely dropping below the level needed to prevent infection. Dogs that received an extra booster at the six-month mark maintained better protection. This suggests that even when a human vaccine does arrive, it will likely require multiple doses and possibly ongoing boosters to remain effective.
What You Can Do Right Now
Without a vaccine, the main medical option after a tick bite is a single dose of the antibiotic doxycycline, taken as post-exposure prophylaxis. The CDC outlines specific criteria for when this makes sense: the bite must have come from a blacklegged tick (the species that carries Lyme), it must have occurred in an area where those ticks are likely infected, and the antibiotic needs to be taken within 72 hours of removing the tick. A tick that’s visibly engorged with blood poses a higher risk than one that’s still flat, because an engorged tick has been feeding long enough to potentially transmit the bacteria.
Doxycycline isn’t appropriate for everyone. People with allergies to the drug, those who are pregnant, or those who are breastfeeding need alternative approaches. For everyone else in a high-risk situation, that single dose is currently the closest thing to a medical safety net after exposure.
Prevention still relies on the basics: wearing treated clothing in tick habitat, doing thorough tick checks after spending time outdoors, and removing attached ticks promptly with fine-tipped tweezers. The combination of quick removal and prophylactic antibiotics when criteria are met is highly effective at preventing Lyme disease, even without a vaccine.